{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-031834","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2022-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.171353+00:00","generated_at":"2026-06-23T08:48:55.726680+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Trevi reports positive Phase 2 CANAL data: Haduvio reduces daytime cough 75% vs 23% placebo","bullets":["Primary endpoint met: placebo-adjusted daytime cough frequency reduction 52.5% (p<0.0001).","Haduvio achieved 76.1% reduction in 24-hour cough frequency vs 25.3% placebo (p<0.0001).","97% of Haduvio subjects had ≥30% reduction in 24-hour cough vs 35% placebo (p<0.0001).","Company aims to initiate Phase 2b in chronic cough IPF in H1 2023, Phase 3 in prurigo nodularis in H1 2023.","Safety consistent with prior trials; most common adverse events: nausea, fatigue, constipation, dizziness."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-031834","json":"https://secwatch.observer/filing/0001564590-22-031834.json","markdown":"https://secwatch.observer/filing/0001564590-22-031834.md","text":"https://secwatch.observer/filing/0001564590-22-031834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/0001564590-22-031834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156459022031834/trvi-8k_20220919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:48:55.726680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}